Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling
Liliana Montella(Ospedale Santa Maria), Giovannella Palmieri(Regione Campania), Mario Giuliano(Regione Campania), Fernanda Picozzi(Federico II University Hospital), Gaetano Facchini(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Luigi Insabato(Federico II University Hospital), Vittorio Riccio(University of Naples Federico II), Margaret Ottaviano(University of Naples Federico II)
Cited by 2
Related Papers
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268